Literature DB >> 22227496

"Delayed death" phenomenon: a synergistic action of cyclophosphamide and exogenous DNA.

Evgenia V Dolgova1, Anastasia S Proskurina, Valeriy P Nikolin, Nelly A Popova, Ekaterina A Alyamkina, Konstantin E Orishchenko, Vladimir A Rogachev, Yaroslav R Efremov, Tatiana D Dubatolova, Anastasia V Prokopenko, Elena R Chernykh, Alexandr A Ostanin, Oleg S Taranov, Vladimir V Omigov, Stanislav N Zagrebelniy, Sergey S Bogachev, Mikhail A Shurdov.   

Abstract

Morbidity and mortality in mice were observed upon administration of exogenous DNA following their pre-treatment with a cytostatic agent cyclophosphamide. Upon intraperitoneal injections, the fragments of exogenous DNA reached bone marrow cells. These cells were also found to internalize up to 1800 kb of exogenous DNA ex vivo. The 18-24 h time frame represents a final stage in the repair of DNA double-strand breaks, so when exogenous DNA was administered within this critical period of time, pathological changes were observed in many target organs. Namely, bone marrow cells underwent a sustained increase in apoptosis. Copy number of B1 and B2 DNA repeats in bone marrow cells remained unchanged, whereas in the control group of animals their levels were significantly decreased. Finally, the bone marrow cells of moribund animals completely lacked lymphoid progenitors, yet the CD34+ hematopoietic stem cell counts were normal. Histopathology analysis suggested that mice died due to accidental involution of lymphoid organs combined with a systemic inflammatory process induced by massive administration of exogenous DNA and depletion of lymphoid lineage.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22227496     DOI: 10.1016/j.gene.2011.12.032

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  13 in total

1.  Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cells.

Authors:  Ekaterina A Potter; Evgenia V Dolgova; Anastasia S Proskurina; Yaroslav R Efremov; Alexandra M Minkevich; Aleksey S Rozanov; Sergey E Peltek; Valeriy P Nikolin; Nelly A Popova; Igor A Seledtsov; Vladimir V Molodtsov; Evgeniy L Zavyalov; Oleg S Taranov; Sergey I Baiborodin; Alexander A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Oncotarget       Date:  2017-02-07

2.  Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called "Karanahan" Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model.

Authors:  Vera Ruzanova; Anastasia Proskurina; Yaroslav Efremov; Svetlana Kirikovich; Genrikh Ritter; Evgenii Levites; Evgenia Dolgova; Ekaterina Potter; Oksana Babaeva; Sergey Sidorov; Oleg Taranov; Alexandr Ostanin; Elena Chernykh; Sergey Bogachev
Journal:  Pathol Oncol Res       Date:  2022-05-27       Impact factor: 2.874

3.  Combination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts.

Authors:  Ekaterina A Alyamkina; Valeriy P Nikolin; Nelly A Popova; Alexandra M Minkevich; Artem V Kozel; Evgenia V Dolgova; Yaroslav R Efremov; Sergey I Bayborodin; Oleg M Andrushkevich; Oleg S Taranov; Vladimir V Omigov; Vladimir A Rogachev; Anastasia S Proskurina; Evgeniy I Vereschagin; Elena V Kiseleva; Maria V Zhukova; Alexandr A Ostanin; Elena R Chernykh; Sergey S Bogachev; Mikhail A Shurdov
Journal:  Cancer Cell Int       Date:  2015-03-19       Impact factor: 5.722

4.  Identification of cancer stem cells and a strategy for their elimination.

Authors:  Evgenia V Dolgova; Ekaterina A Alyamkina; Yaroslav R Efremov; Valeriy P Nikolin; Nelly A Popova; Tamara V Tyrinova; Artem V Kozel; Alexandra M Minkevich; Oleg M Andrushkevich; Evgeniy L Zavyalov; Alexander V Romaschenko; Sergey I Bayborodin; Oleg S Taranov; Vladimir V Omigov; Ekaterina Ya Shevela; Vyacheslav V Stupak; Sergey V Mishinov; Vladimir A Rogachev; Anastasia S Proskurina; Vladimir I Mayorov; Mikhail A Shurdov; Alexander A Ostanin; Elena R Chernykh; Sergey S Bogachev
Journal:  Cancer Biol Ther       Date:  2014-10       Impact factor: 4.742

5.  Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.

Authors:  Anastasia S Proskurina; Tatiana S Gvozdeva; Ekaterina A Alyamkina; Evgenia V Dolgova; Konstantin E Orishchenko; Valeriy P Nikolin; Nelly A Popova; Sergey V Sidorov; Elena R Chernykh; Alexandr A Ostanin; Olga Y Leplina; Victoria V Dvornichenko; Dmitriy M Ponomarenko; Galina S Soldatova; Nikolay A Varaksin; Tatiana G Ryabicheva; Peter N Uchakin; Stanislav N Zagrebelniy; Vladimir A Rogachev; Sergey S Bogachev; Mikhail A Shurdov
Journal:  BMC Cancer       Date:  2015-03-13       Impact factor: 4.430

6.  Properties of internalization factors contributing to the uptake of extracellular DNA into tumor-initiating stem cells of mouse Krebs-2 cell line.

Authors:  Evgeniya V Dolgova; Ekaterina A Potter; Anastasiya S Proskurina; Alexandra M Minkevich; Elena R Chernych; Alexandr A Ostanin; Yaroslav R Efremov; Sergey I Bayborodin; Valeriy P Nikolin; Nelly A Popova; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Stem Cell Res Ther       Date:  2016-05-25       Impact factor: 6.832

7.  A strategy to eradicate well-developed Krebs-2 ascites in mice.

Authors:  Ekaterina A Potter; Evgenia V Dolgova; Anastasia S Proskurina; Alexandra M Minkevich; Yaroslav R Efremov; Oleg S Taranov; Vladimir V Omigov; Valeriy P Nikolin; Nelly A Popova; Sergey I Bayborodin; Alexander A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Mikhail A Shurdov; Sergey S Bogachev
Journal:  Oncotarget       Date:  2016-03-08

8.  Efficacy of a new cancer treatment strategy based on eradication of tumor-initiating stem cells in a mouse model of Krebs-2 solid adenocarcinoma.

Authors:  Ekaterina A Potter; Anastasia S Proskurina; Genrikh S Ritter; Evgenia V Dolgova; Valeriy P Nikolin; Nelly A Popova; Oleg S Taranov; Yaroslav R Efremov; Sergey I Bayborodin; Aleksandr A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Oncotarget       Date:  2018-06-19

9.  Identification of the xenograft and its ascendant sphere-forming cell line as belonging to EBV-induced lymphoma, and characterization of the status of sphere-forming cells.

Authors:  Evgeniya V Dolgova; Daria D Petrova; Anastasia S Proskurina; Genrikh S Ritter; Polina E Kisaretova; Ekaterina A Potter; Yaroslav R Efremov; Sergey I Bayborodin; Tatiana V Karamysheva; Margarita V Romanenko; Sergey V Netesov; Oleg S Taranov; Aleksandr A Ostanin; Elena R Chernykh; Sergey S Bogachev
Journal:  Cancer Cell Int       Date:  2019-05-06       Impact factor: 5.722

10.  Novel Cancer Stem Marker and Its Applicability for Grading Primary Human Gliomas.

Authors:  Evgeniya V Dolgova; Sergey V Mishinov; Anastasiya S Proskurina; Ekaterina A Potter; Yaroslav R Efremov; Sergey I Bayborodin; Tamara V Tyrinova; Vyacheslav V Stupak; Alexandr A Ostatin; Elena R Chernykh; Sergey S Bogachev
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.